Murielle R.
- Country
- France
- Department
- Département d’Hématologie
Research Overview
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase 3 Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone vs. Pomalidomide, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Evaluation of Minimal Residual Disease-Based Strategy with Teclistamab Post-Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 128 of 263 partner sites.
Specializations
Multiple Myeloma Management
Specializes in innovative treatments for multiple myeloma, with particular focus on both newly diagnosed cases and relapsed/refractory disease states. The investigator has extensive experience in evaluating novel therapeutic combinations incorporating monoclonal antibodies and emerging treatment modalities.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- Transplant-Ineligible Patient Care
Expertise includes assessment of treatment responses and optimization of therapeutic strategies for various patient populations.
Immunotherapy Approaches
Focuses on advancing immunotherapeutic strategies in hematologic malignancies, particularly investigating novel agents such as T-cell redirectors and targeted therapies. Works with cutting-edge treatments including innovative antibody-based therapies.
- Bispecific Antibodies
- Combination Immunotherapy
- Novel Agent Development
Specializes in evaluating immune-based approaches for optimal disease control and treatment outcomes.
Light Chain Amyloidosis
Conducts research in AL amyloidosis, investigating therapeutic approaches for patients with previously treated disease. Expertise extends to hematologic response assessment and novel treatment strategies.
- Treatment-Resistant Disease
- Novel Therapeutic Approaches
- Response Evaluation
Focuses on developing effective treatments for this challenging plasma cell disorder.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.